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Background: Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in
diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited.
Patients and methods: Here, we applied the computational method CIBERSORT to generate a 1028-gene matrix
incorporating signatures of 17 immune and stromal cytotypes. Then, we carried out a deconvolution on publicly available GEP
data of 482 untreated DLBCLs to reveal associations between clinical outcomes and proportions of putative tumor-infiltrating
cell types. Forty-five genes related to peculiar prognostic cytotypes were selected and their expression digitally quantified by
NanoString technology on a validation set of 175 formalin-fixed, paraffin-embedded DLBCLs from two randomized trials. Data
from an unsupervised clustering analysis were used to build a model of clustering assignment, whose prognostic value was also
assessed on an independent cohort of 40 cases. All tissue samples consisted of pretreatment biopsies of advanced-stage
DLBCLs treated by comparable R-CHOP/R-CHOP-like regimens.
Results: In silico analysis demonstrated that higher proportion of myofibroblasts (MFs), dendritic cells, and CD4þ T cells
correlated with better outcomes and the expression of genes in our panel is associated with a risk of overall and progression-
free survival. In a multivariate Cox model, the microenvironment genes retained high prognostic performance independently of
the cell-of-origin (COO), and integration of the two prognosticators (COOþ TME) improved survival prediction in both
validation set and independent cohort. Moreover, the major contribution of MF-related genes to the panel and Gene Set
Enrichment Analysis suggested a strong influence of extracellular matrix determinants in DLBCL biology.
VC The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Conclusions: Our study identified new prognostic categories of DLBCL, providing an easy-to-apply gene panel that powerfully
predicts patients’ survival. Moreover, owing to its relationship with specific stromal and immune components, the panel may
acquire a predictive relevance in clinical trials exploring new drugs with known impact on TME.
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Introduction
Reliable prognostic stratification at diagnosis and improvement
of first-line/salvage strategies represent unmet clinical needs in
diffuse large B-cell lymphoma (DLBCL). Gene expression
profiling (GEP) studies suggested that patients’ outcome is
entwined with a remarkable heterogeneity of both malignant
clone and cellular/extracellular microenvironment, and
unveiled prognostic cell-of-origin (COO) subtypes of DLBCL,
namely GCB and ABC, driven by peculiar oncogenic pathways
[1]. This prompted the adoption of immunohistochemical
algorithms or NanoString-based assays, as GEP surrogates, for
prognostic purpose [2].
Parallel studies emphasized the prognostic role of genes related
to tumor microenvironment (TME) [3]. Lenz et al. demonstrated
that the ‘Stromal-1’ and ‘Stromal-2’ signatures correlate with
good and poor outcome in R-CHOP-treated patients, respective-
ly, independently of COO [4]. However, these signatures failed in
recognizing definite TME cytotypes with prognostic significance,
and their practical use was limited by the lack of standardized
assays applicable to formalin-fixed, paraffin-embedded (FFPE)
samples. Despite several attempts [5–9], neither specific, nor re-
producible TME biomarkers have been thus far identified, cap-
able of predicting patients’ outcome.
Computational methods of GEP deconvolution allow high-
sensitivity discrimination of cell subsets within complex tissues,
as tumors [10]. Such approaches provide quantitative/functional
information also on rare tumor-infiltrating elements, offering the
unprecedented opportunity of reanalyzing available genomic
data to explore correlation between TME cells and clinical
outcomes.
Here, we applied the computational algorithm CIBERSORT to
GEP datasets from pretreatment DLBCL biopsies to draw a map
of immune and stromal components of TME. We identified
microenvironmental prognostic genes and used the NanoString
technology to develop a reproducible assay, which was validated
in independent DLBCL cohorts.
Materials and methods
Patient cohorts
We selected two homogeneous cohorts of 175 and 40 patients
with newly diagnosed, nodal DLBCL, not otherwise specified, from
two multicenter trials (RHDS0305 [11] and DLCL04 [12]) and three
monocenter ‘real-life’ selections from IRCCS - Istituto Tumori
‘Giovanni Paolo II’ of Bari (Italy), S. Orsola-Malpighi Policlinic,
Bologna (Italy) and Hospital Clinic, Barcelona (Spain), respectively.
Characteristics of the patients and selection criteria are shown in
Figure 1A and detailed in supplementary methods, available at Annals
of Oncology online.
CIBERSORT analyses, NanoString-based gene quan-
tification and building of a Random Forest-based
model for survival prediction
A CIBERSORT-based deconvolution of GEP datasets (GSE10846 and
GSE34171) from 482 DLBCLs was carried out using a 1028-gene signa-
ture matrix customized by normalizing referenced microarray data
(Affymetrix) from 13 immune and 4 stromal cell types, according to
CIBERSORT instructions (https://cibersort.stanford.edu/; supplemen-
tary Tables S1 and S2, available at Annals of Oncology online). DLBCL
cases were stratified in ‘good’ and ‘poor’ outcome subgroups [according
to overall survival (OS)] and only those cell types showing significantly
different infiltration percentages between groups were analyzed. Then,
the most expressed genes (log2 transformed >12) as well as those identi-
fied by a Random Forest analysis as the ‘top-30’ from each cytotype pro-
vided a selection of 150 genes (supplementary Figures S1 and S2,
available at Annals of Oncology online). Among these, only genes showing
a significantly different expression between ‘poor’ and ‘good’ subgroups
were incorporated in a definitive prognostic panel of 45 TME-related
genes (supplementary Figure S3 and Table S3, available at Annals of
Oncology online). Further details are provided in supplementary meth-
ods, available at Annals of Oncology online. The prognostic performance
of the panel was firstly assessed by an unsupervised clustering and sur-
vival analysis of 218 cases homogeneously selected (stages III–IV) from
the GSE10846 dataset [4] (fresh/frozen biopsies). Gene expression levels
were extracted from a normalized matrix and a long-rank test used to
compare OS in the clustered samples.
Expression of TME genes and COO were assessed by the nCounter
Analysis System (NanoString Technology) on the 175 FFPE cases
enrolled in trials. Also, 79 of these cases were randomly selected as tech-
nical replicate using a second nCounter Analysis System located at a dif-
ferent Institute. Details are described in supplementary methods,
available at Annals of Oncology online.
A Random Forest classifier was built on the expression of TME genes
from the validation set and applied to 40 ‘real life’ cases to perform a
TME clustering and survival analysis. Finally, a composite model of sur-
vival prediction was developed by integrating the prognostic contribu-
tion of both COO and TME data, and stratifying cases (both validation
and ‘real life’ cohorts) into high, intermediate and low risk categories.
The overall study design is outlined in Figure 1B.
Gene set enrichment analysis and in situ staining
Gene set enrichment analysis (GSEA) [13] was run on three independent
GEP datasets (GSE10846 [4], GSE34171 [14], and GSE12195 [15]).
Immunohistochemical and immunofluorescence studies were carried
out on representative DLBCL cases (supplementary methods, available at
Annals of Oncology online).
Statistical analysis and risk categories
Principal component analysis (PCA) was carried out to distinguish cell
subsets in the customized matrix. Comparison between groups was carried
out by independent t-test (two tails, unequal variance) and Mann–
Whitney nonparametric test. PCA, Heatmaps, Kaplan–Meier estimator of
survival and P values were produced using ‘R’ statistical software. Long-
rank test was used to compare OS and progression-free survival (PFS)
among patients in different groups. Analysis of parameters included dis-
tance calculations by the Euclidian methodology; Ward’s method was
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applied for cluster aggregation. Multivariate and univariate analyses were
constructed through the Cox proportional hazards regressionmodel.
Results
CIBERSORT-based enumeration of DLBCL-
infiltrating cell fractions has prognostic
significance
PCA confirmed that the customized matrix clearly distinguishes
two main cellular groups including immune cells of both lymph-
oid and myeloid derivation, and cells of mesenchymal origin, re-
spectively (supplementary Figure S1A, available at Annals of
Oncology online). However, among the lymphoid component a
variable degree of transcriptional overlap was expected between
tumor and B-lineage cells, as previously described [16]. In fact,
our analysis revealed that, among immune subsets, memory B
cells (as expected in a B-cell malignancy), natural killer (NK) acti-
vated cells, dendritic cells (DCs), CD4þ T cells, and M2-type
macrophages were the most represented cell fractions within
DLBCL microenvironment, whereas myofibroblasts (MFs) pre-
vailed among the mesenchymal cytotypes (supplementary Figure
S1B, available at Annals of Oncology online). When correlated to
clinical outcome, the cases with higher proportions of MFs, DCs,
and CD4þ T cells showed significantly longer OS (P¼ 0.002,
P¼ 0.02, and P¼ 0.004, respectively), whereas activated NK and
plasma cells (PCs) were more represented in patients with poorer
outcome (P¼ 0.001 for NK). Owing to the potential overlap be-
tween transcriptional programs of PCs and malignant B cells of
DLBCL, PCs were not included in subsequent in silico analyses.
Stratification according to median percentage of infiltration of
MFs, DCs, and CD4þ T cells confirmed their in silico prognostic
significance, since Kaplan–Meier curves indicated their direct
correlation with a longer OS. On the contrary, activated NK cells
correlated with a significantly shorter OS (supplementary Figure
S1C, available at Annals of Oncology online).
Development of a 45-gene microenvironment
panel
DLBCL cases were dichotomized according to the median infil-
tration percentage of cell types endowed with prognostic signifi-
cance in silico. Subsequent analyses provided a selection of 30
MF-, 10 DC-, and 5 CD4þ T-cell-related transcripts, which was
incorporated in a 45-gene microenvironment panel for the valid-
ation phase (supplementary Figures S2 and S3 and Tables S1–S3,
available at Annals of Oncology online). Moreover, a GSEA
showed a significant enrichment of genes biologically linked with
cytotypes consistent with the high expression of genes in our MF-
, DC- and CD4þ T-cell signatures (supplementary Table S4,
available at Annals of Oncology online), demonstrating that they
were representative of these prognostically relevant cell types.
The 45-gene microenvironment panel stratifies
DLBCL patients on both fresh/frozen- and FFPE-
derived RNA
Based on the expression of the 45 genes of the TME panel, an un-
supervised clustering analysis efficiently stratified cases from the
GSE10846 dataset in three distinct subgroups showing signifi-
cantly different OS (P< 0.0001) (supplementary Figure S4, avail-
able at Annals of Oncology online). Using the NanoString
technology on 175 FFPE biopsy samples of the validation cohort,
the unsupervised hierarchical clustering analysis stratified cases
into high, intermediate, and low gene expression clusters
(Figure 2A) comprising patients with significantly different OS
(Figure 2B) and PFS (Figure 2C). In particular, the cases with
lower gene expression (cluster 3) showed significantly worse sur-
vival (median 5-year OS and PFS of 60.7% and 58.9%, respective-
ly) than those at intermediate (cluster 2, 91.5% and 84.7%) and
higher expression (cluster 1, 83.2% and 73.2%). When stratified
according to the expression of specific cytotype-related genes, the
unsupervised clustering generated subgroups with similar prog-
nostic trend (supplementary Figure S5, available at Annals of
Oncology online). In fact, Kaplan–Meier curves showed signifi-
cantly different OS and PFS among expression clusters of MF-
related genes (supplementary Figure S5A, available at Annals of
Oncology online), whereas DC and CD4þ T-cell signatures identi-
fied subgroups with only significantly different OS (supplemen-
tary Figure S5B–C, available at Annals of Oncology online).
Notably, a Cox multivariate model of OS indicated that the prog-
nostic performance of the gene panel is independent of COO
classification and international prognostic index (IPI) score
(Figure 3A and supplementary Table S5, available at Annals of
Oncology online). Finally, the analytical validity of these results
was also confirmed by their inter-laboratory reproducibility sup-
ported by the analysis of 79 technical replicates using a
NanoString platform placed in a different laboratory (data not
shown).
Integration of TME- and COO-based data from 175 patients in
the validation cohort (supplementary Figure S6, available at
Annals of Oncology online) produced a survival model identifying
three different risk categories. The high-risk category includes
ABC cases belonging to cluster 3, showing the worst outcomes;
the intermediate-risk category comprises ABC patients assigned
to cluster 1 or 2, and GCB or unclassified to cluster 3, with longer
OS and PFS; and the low-risk category containing GCB or unclas-
sified cases belonging to cluster 1 or 2 (Figure 3B). The reliability
of this model was also assessed on 40 ‘real-life’ cases assigned to a
certain TME cluster by a Random-Forest-based model built on
the validation set. Interestingly, the risk categories produced an
efficient survival prediction also for real-life cases (Figure 3C),
which expectedly showed a global worse outcome compared with
clinical trial cases, probably since they lacked the same selection
procedure.
Taken together, these findings indicate that the microenviron-
ment gene panel retains an independent prognostic power that,
in combination with COO, acquires a remarkable capability of
survival prediction, identifying patients at extreme risk within
either the GCB or the unclassified or the ABC subsets.
Potential microenvironment determinants of
DLBCL prognostic categories
By applying GSEA, we found a significant enrichment of the
‘Stromal-1’ signature [4] in cases with higher MF infiltration
[normalized enrichment score (NES)¼ 1.60, false discovery rate
(FDR)¼ 0.06]. Such cases were also enriched in distinctive
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47
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Figure 1. Characteristics of DLBCL patients in the study cohorts and overall study design. (A) Clinical data of patients form multicentric trials
and ‘real-life’ cohort. (B) GEP data from 482 fresh-frozen DLBCL biopsies were analyzed by CIBERSORT to obtain a set of prognostic cytotype-
related genes that were incorporated in a deﬁnitive 45-gene TME panel. The prognostic power of the panel was ﬁrst assessed on 218
selected cases from the in silico cohort. Subsequent validation was carried out by NanoString technology on 175, FFPE samples from clinical
trial and 40 ‘real-life’ patients. In addition, 79 randomly selected cases from the clinical-trial validation cohort were analyzed on a second
NanoString Platform, as technical replicate. Based on the expression matrix from the 175 validation cases, a Random Forest classiﬁer was built
to assign each of the 40 ‘real life’ cases to a certain gene expression cluster and perform survival analysis. Thus, a composite model of survival
prediction was developed by integrating the prognostic contribution of both TME and COO. FFPE, formalin-ﬁxed parafﬁn embedded; CHT,
chemotherapy; ASCT, autologous stem cell transplantation; COO, cell-of-origin; IPI, international prognostic index; TME, tumor
microenvironment.
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transcriptional programs of fibroblastic reticular cells (FRCs)
and alpha-Smooth Muscle Actin (SMA)-expressing elements
(NES¼ 1.88, FDR¼ 0.01 and NES¼ 2.5, FDR< 104, respect-
ively) [17]. Consistently, the cases with higher alpha-SMA ex-
pression showed a significant enrichment of FRC genes
(supplementary Figure S7A, available at Annals of Oncology on-
line), and those with the highest MF infiltration were enriched in
genes implicated in extracellular matrix (ECM) remodeling (sup-
plementary Figure S7B, available atAnnals of Oncology online).
We in situ analyzed the expression of proteins encoded by four
fronting genes of the MF signature, namely Fibronectin,
Collagen-I, Laminin, and Collagen-IV. Double-marker immuno-
fluorescence on representative DLBCLs belonging to different
clusters showed high variability in both distribution and intensity
of ECMmarkers (supplementary Figure S8, available at Annals of
Oncology online). In some cases, Fibronectin and Collagen-I
formed a diffuse interstitial meshwork, while in others they
mainly co-localized at perivascular foci. On the contrary,
Laminin and Collagen-IV distribution varied according to the
microvascular density. Also, the alpha-SMA staining revealed
higher densities of MF infiltration in samples from cases with fa-
vorable outcome (supplementary Figure S8, available at Annals of
Oncology online). Overall, the extreme variability of ECM protein
expression by in situ immunostaining does not support its use as
a reliable assay to surrogate the expression of the relative TME
prognostic genes.
Discussion
In a quite dogmatic view of DLBCL composition, the paucity of
TME suggests that malignant clones grow independently from
microenvironment stimuli [18]. Only few GEP studies [4, 5] in-
dicate that stromal signatures can predict survival, but the clinical
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Figure 2. Prognostic subgroups of DLBCL based on microenvironment gene expression. (A) The heatmap depicts the unsupervised hier-
archical clustering of 175 DLBCL cases (NanoString technology) and identiﬁes three different clusters according to high (cluster 1), intermedi-
ate (cluster 2), and low expression (cluster 3) of all genes in the TME panel. The relative levels of transcripts are indicated according to the
color scale. Each row group comprises genes associated to speciﬁc tumor-inﬁltrating cell populations and each column a biopsy sample.
Kaplan–Meier curves of OS (B) and PFS (C) show that patients in clusters 1 and 2 have signiﬁcantly longer OS and PFS than those in cluster 3.
Annals of Oncology Original article
Volume 29 | Issue 12 | 2018 doi:10.1093/annonc/mdy450 | 2367
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/29/12/2363/5126827 by D
ivisione C
oordinam
ento Biblioteche Statale M
I user on 21 January 2019
1.00
High
IPI Intermediate–High
1
3
2Clusters
Unclassified
ABC
GCBCOO Reference
P
Reference
Reference
4.89 (2.17, 11.05)
4.23 (1.56, 11.48)
3.05 (1.04, 9.00)
2.80 (1.41, 5.53)
1 2 5 10
1.56 (0.60, 4.07)
Variable
A
B
C
N Hazard ratio
103
38
34
60
57
58
128
47 0.003
0.043
0.005
0.365
<0.001
0.75
0.50
0.25
0.00
R
is
k
R
is
k
R
is
k
R
is
k
Pr
ob
ab
ilit
y 
of
 o
ve
ra
ll s
ur
viv
al
Pr
ob
ab
ilit
y 
of
 o
ve
ra
ll s
ur
viv
al
Pr
ob
ab
ilit
y 
of
 p
ro
gr
es
sio
n–
fre
e 
su
rv
iva
l
Pr
ob
ab
ilit
y 
of
 p
ro
gr
es
sio
n–
fre
e 
su
rv
iva
l
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
0 30
High 23 11 10 3
Low 103 94 58 18
Intermediate 49 33 29 7
23 11 10 3
103 85 53 15
49 31 27 6
9 0 0 0
18 8 4 0
13 3 0 0
9 1 0 0
18 10 6 0
13 7 2 2
High
Low
Intermediate
High
Low
Intermediate
High
Low
Intermediate
P < 0.0001 P = 0.00085
P = 0.0011P = 0.00022
60
Time (months) Time (months)
Time (months)Time (months)
Time (months) Time (months)
Time (months)
Number at riskNumber at risk
Number at risk Number at risk
Time (months)
90
0 30 60 90 0 30 60 90
Risk index
ABC
Cluster 1
Cluster 2
Cluster 3 High Intermediate Intermediate
Intermediate
Intermediate
Low
Low
Low
Low
GCB undeterm.
0 30 60 90
0 30 60 900 30 60 90
0 30 60 900 30 60 90
Risk High Low Intermediate
Figure 3. COO/TME combined model for survival prediction in DLBCL. (A) Forest plot of multivariable hazard ratios for OS. Multivariable ana-
lysis was adjusted for COO, clusters of microenvironment gene expression and IPI. (B) Kaplan–Meier curves showing OS (left panel) and PFS
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application of such signatures is restrained by the lack of robust,
reproducible and cost-effective biomarkers. In addition, the
above-mentioned studies were mostly carried out on fresh or fro-
zen samples, which are not available in most patients.
Herein, we applied a computational strategy to reanalyse GEP
from whole-tissue biopsies and resolve in silico the cellular com-
ponents of DLBCL.We found that a prevalence of MFs, DCs, and
CD4 T cells and their gene signatures predict significantly longer
survival after chemoimmunotherapy. From a clinical point of
view, we capitalized GEP data to validate a new risk model that
purely reflects the cellular composition of TME and categorize
DLBCL patients in new COO-independent prognostic sub-
groups. Neither early-stage, nor high-grade ‘double hit’ patients
have been included in our validation cohorts to avoid
potential prognostic biases relying on low tumor burden or mo-
lecular aggressiveness of the disease. This emphasizes that current
COO classification may fail in discriminating subsets of patients
whose prognosis could be better predicted by a combined COO/
microenvironment assessment. We validated a NanoString-
based assay that provides simultaneous COO and TME informa-
tion, and a Random-Forest model to facilitate the assignment of
cases to a certain TME gene expression cluster in the clinical
practice.
From a biological point of view, our evidence raises key ques-
tions on the nature and role of stromal elements in the patho-
physiology of lymph nodes [19]. It is conceivable that cells
recognized by CIBERSORT as MFs belong to a resident pool of
FRCs, as immunologically specialized stromal elements [20].
Consistently, our signature includes genes encoding ECMmol-
ecules, as collagens (COL-1, -3, -4, -5, -6), proteoglycans and
glycoproteins (Lumican, Byglican, Laminin, Fibronectin,
SPARC), matrix metalloproteinases (MMPs), metallopeptidase
inhibitors (TIMP1, TIMP3), adhesion molecules (ALCAM,
AMICA1, Periostin), and regulators (TGFBI). GSEA indicated
a significant enrichment of FRC-related genes involved in ECM
organization in highly MF-infiltrated cases. The ‘Stromal-1’
signature [4] was also found enriched in these cases, suggesting
that a specific pool of stromal cells, not clearly recognizable by
GEP, may functionally influence the DLBCL biology. This is
consistent with the attitude of stromal elements to react to in-
flammatory stimuli and remodel the microarchitecture of
lymph nodes to orchestrate the immune response [17, 21].
Monocyte/macrophage precursors, B and T lymphocytes as
well as other antigen-presenting cells (APCs), including DCs,
are recruited within tumor milieu by gradients of chemokines,
cytokines and growth factors [22] and traffic within the lymph
node along collagen scaffolds mainly regulated by stromal cells
[23, 24]. In turn, fibroblastic and immune cells participate to
the local synthesis of soluble mediators active on APCs, effector
cells and tumor cells themselves [25]. Some of the CD4þ T-cell-
and DC-related genes in our panel, namely ALCAM, AMICA1,
COL4A2, TNFSF13B, and SMAD1, encode activators of T lym-
phocytes and APCs via adhesion and paracrine mechanisms.
Our findings suggest a functional relationship between MFs,
ECM and immune system components in DLBCL, where the
TME heterogeneity reflects unique paracrine and spatially
organized interactions between tumor, mesenchymal and spe-
cialized subsets of immune cells [23]. This crosstalk, which
may involve other lymphoid and myeloid cells as PCs, CD8þ T
cells, NKs, and T-reg contributes to the immune control of the
malignant clone and impacts the efficacy of chemo-
immunotherapy [26, 27].
At a clinical level, the prognostic impact of CD4þ T cells and
DCs in DLBCL has been previously reported [7], emphasizing the
idea that patients with consensual activation of stromal and im-
mune elements benefit from an empowered immune-
surveillance in terms of survival. This study, however, remains
uninformative about whether peculiar quantitative/functional
assets of nontumor cells in lymph nodes precedes or follows
tumor initiation and growth. Also, the role of some ECM pro-
teins, such as SPARC, remains ambiguous since it may exert op-
posite influence on the tumor clone [28]. It controls the
inflammatory milieu by remodeling ECM and its experimental
deficiency promotes lymphomagenesis in vivo [29], suggesting
again that peculiar stromal/immune programs may affect tumor
behavior. Limitations of our study also include its retrospective
nature and the small ‘real-life’ sample size. Further validation of
the proposed model is required on large-scale, prospective
cohorts of patients at different disease stages or selected accord-
ing to the more recent molecular variants of DLBCL [30].
On the other hand, our findings indicate that the assessment
of certain transcriptional programs, as those detected by our
gene panel, may provide more reliable prognostic information
than immunohistochemistry surrogates. We believe that com-
putational approaches decoding ‘big’ genomic data, followed by
proper validation, may capture functional processes linked to
definite cytotypes within TME, and NanoString technology for
gene quantification from FFPE tissues is particularly advanta-
geous in term of feasibility, reproducibility and costs, and wor-
thy of being routinely included in the diagnostic/prognostic
workflow. Finally, although this work does not provide definite
therapeutic targets related to TME, it prompts future investiga-
tions to assess whether our model can be predictive for patients
treated by novel drugs with broad modulatory properties on
TME.
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